Key facts
- SquareMind’s last known valuation is $1.1M (Mar 2019).
- It has raised $110K; the latest was Later Stage VC in Feb 2026.
- Notable investors include Bpifrance, European Innovation Council, Entrepreneurs First, Calm/Storm Ventures, Sonder Capital Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for SquareMind
- ·The full record, as it builds
Funding rounds
No funding rounds for SquareMind are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SquareMind
Developer of robotic medical equipment designed to transform non-invasive healthcare. The company's equipment is equipped with third-dimension construction software for full-body mapping to detect skin cancer, enabling physicians to track the growth of moles on the body using off-the-shelf robots.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2019
- Employees
- 18
- Website
- squaremind.com/
- Ownership
- Privately Held (backing)
SquareMind doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SquareMind shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SquareMind in its N-PORT filings yet. We sweep new filings monthly.